Here, we describe the molecules involved in platelet–tumor interaction, specially focusing on the mechanisms by which PCLP1, a transmembrane sialomucin with selectin-ligand activity, participates in platelet–tumor aggregate formation. The gene discussed is PODXL; the disease is neoplasm.